Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LIGAND PHARMACEUTICALS INCLGND · Entity 3825 | Chief Financial Officer | August 12, 2026 | August 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LIGAND PHARMACEUTICALS INC
Report date August 12, 2026 · Filed August 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,696 |
Ending reported balance
After 2026-08-12 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-08-12 · Exercise / conversion · Acquired 16,179 · Balance 43,875 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. Row 2 · 2026-08-12 · Exercise / conversion · Acquired 2,074 · Balance 45,949 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. Row 3 · 2026-08-12 · Exercise / conversion · Acquired 2,869 · Balance 48,818 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. Row 4 · 2026-08-12 · Exercise / conversion · Acquired 7,171 · Balance 55,989 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. Row 5 · 2026-08-12 · Exercise / conversion · Acquired 3,348 · Balance 59,337 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. Row 6 · 2026-08-12 · Sale · Disposed 31,641 · Balance 27,696 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $292.0098 to $292.0846. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.75 · Expires 2030-02-13 | Direct | 0 |
Reported balance
After 2026-08-12 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-12 · Exercise / conversion · Disposed 2,869 · Balance 0 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. F3: The original grant of 4,039 stock options vests and is exercisable as to approximately 15% of the underlying shares on August 13, 2020, approximately 70% of the underlying shares in 28 substantially equal monthly installments beginning on September 13, 2020, and approximately 15% of the underlying shares in 12 substantially equal monthly installments thereafter. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $57.22 · Expires 2030-10-01 | Direct | 0 |
Reported balance
After 2026-08-12 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-08-12 · Exercise / conversion · Disposed 7,171 · Balance 0 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. F4: The stock option vests and is exercisable as to approximately 14% of the underlying shares on April 1, 2021, approximately 73% of the underlying shares in 32 substantially equal monthly installments on May 5, 2021, and approximately 13% of the underlying shares in 10 substantially equal monthly installments thereafter. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.84 · Expires 2032-05-05 | Direct | 0 |
Reported balance
After 2026-08-12 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-12 · Exercise / conversion · Disposed 16,179 · Balance 0 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. F5: The stock option vests and is exercisable as to approximately 14% of the underlying shares on August 5, 2022, approximately 64% of the underlying shares in 28 substantially equal monthly installments beginning on September 5, 2022, and approximately 22% of the underlying shares in 12 substantially equal monthly installments thereafter. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.74 · Expires 2029-02-11 | Direct | 0 |
Reported balance
After 2026-08-12 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-08-12 · Exercise / conversion · Disposed 3,348 · Balance 0 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. F6: The stock option vests and is exercisable as to approximately 13% of the underlying shares on August 11, 2019, and the remaining of the underlying shares in 40 substantially equal monthly installments thereafter. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.04 · Expires 2029-02-01 | Direct | 0 |
Reported balance
After 2026-08-12 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-08-12 · Exercise / conversion · Disposed 2,074 · Balance 0 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. F7: The stock option vests and is exercisable as to approximately 16% of the underlying shares on August 1, 2019, approximately 74% of the underlying shares in 28 substantially equal monthly installments beginning on September 1, 2019, and approximately 10% of the underlying shares in 12 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1.
F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $292.0098 to $292.0846. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The original grant of 4,039 stock options vests and is exercisable as to approximately 15% of the underlying shares on August 13, 2020, approximately 70% of the underlying shares in 28 substantially equal monthly installments beginning on September 13, 2020, and approximately 15% of the underlying shares in 12 substantially equal monthly installments thereafter.
F4: The stock option vests and is exercisable as to approximately 14% of the underlying shares on April 1, 2021, approximately 73% of the underlying shares in 32 substantially equal monthly installments on May 5, 2021, and approximately 13% of the underlying shares in 10 substantially equal monthly installments thereafter.
F5: The stock option vests and is exercisable as to approximately 14% of the underlying shares on August 5, 2022, approximately 64% of the underlying shares in 28 substantially equal monthly installments beginning on September 5, 2022, and approximately 22% of the underlying shares in 12 substantially equal monthly installments thereafter.
F6: The stock option vests and is exercisable as to approximately 13% of the underlying shares on August 11, 2019, and the remaining of the underlying shares in 40 substantially equal monthly installments thereafter.
F7: The stock option vests and is exercisable as to approximately 16% of the underlying shares on August 1, 2019, approximately 74% of the underlying shares in 28 substantially equal monthly installments beginning on September 1, 2019, and approximately 10% of the underlying shares in 12 substantially equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 16, 2025 Filed Dec 18, 2025 21:19 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 652 | $92.65 | $60,407.80 |
DisclosureSEC source: 0002001011-25-000127 · edgardoc.xml · nonDerivative · entry 4 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 21:19 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 285 | $63.62 | $18,131.70 |
DisclosureSEC source: 0002001011-25-000127 · edgardoc.xml · nonDerivative · entry 3 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,734 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 21:19 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 69 | $57.22 | $3,948.18 |
DisclosureSEC source: 0002001011-25-000127 · edgardoc.xml · nonDerivative · entry 2 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,449 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 21:19 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 1,194 | $52.84 | $63,090.96 |
DisclosureSEC source: 0002001011-25-000127 · edgardoc.xml · nonDerivative · entry 1 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 23:36 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 1,804 | $188.31 | $339,711.24 |
DisclosureSEC source: 0002001011-25-000125 · edgardoc.xml · nonDerivative · entry 1 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,186 Read SEC document |
| December 05, 2025 Filed Dec 10, 2025 01:06 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,862 | $184.87 | $344,227.94 |
DisclosureSEC source: 0002001011-25-000123 · edgardoc.xml · nonDerivative · entry 1 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,990 F1 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 23:32 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | OtherCommon Stock | 224 | $91.08 | $20,401.36 |
DisclosureSEC source: 0002001011-25-000051 · edgardoc.xml · nonDerivative · entry 1 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,852 F1 · kind: These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| May 09, 2025 Filed May 14, 2025 00:04 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | PurchaseCommon Stock | 500 | $104.40 | $52,200.00 |
DisclosureSEC source: 0002001011-25-000028 · edgardoc.xml · nonDerivative · entry 2 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,932 F1 · kind: The reporting person's purchase of Ligand Pharmaceuticals Incorporated ("Ligand") common stock reported herein might be deemed matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 1,500 shares, with the reporting person's sale of 2,104 shares of Ligand common stock at the highest price of $116.71 per share on December 23, 2024. Accordingly, the reporting person has paid to Ligand, $18,975, representing the full amount of any profit realized if this were to be deemed to be a short-swing transaction. F2 · balance_after: The total includes 69 shares acquired on December 31, 2024, through the Issuer's Employee Stock Purchase Plan (ESPP). Read SEC document |
| May 09, 2025 Filed May 14, 2025 00:04 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | PurchaseCommon Stock | 1,000 | $103.89 | $103,890.00 |
DisclosureSEC source: 0002001011-25-000028 · edgardoc.xml · nonDerivative · entry 1 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,432 F1 · kind: The reporting person's purchase of Ligand Pharmaceuticals Incorporated ("Ligand") common stock reported herein might be deemed matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 1,500 shares, with the reporting person's sale of 2,104 shares of Ligand common stock at the highest price of $116.71 per share on December 23, 2024. Accordingly, the reporting person has paid to Ligand, $18,975, representing the full amount of any profit realized if this were to be deemed to be a short-swing transaction. F2 · balance_after: The total includes 69 shares acquired on December 31, 2024, through the Issuer's Employee Stock Purchase Plan (ESPP). Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 23:55 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantEmployee Stock Option (right to buy) · Derivative | 32,717 | $0.00 Strike: $115.26 | $0.00 |
DisclosureSEC source: 0002001011-25-000015 · edgardoc.xml · derivative · entry 3 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,717 Underlying: Common Stock · 32,717 shares Expires 2035-03-04 F3 · derivative.exercise_date: The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 23:55 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 7,484 | $0.00 | $0.00 |
DisclosureSEC source: 0002001011-25-000015 · edgardoc.xml · nonDerivative · entry 2 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,363 F2 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on February 15, 2026; February 15, 2027; and February 15, 2028, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 23:55 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 5,000 | $115.03 | $575,148.50 |
DisclosureSEC source: 0002001011-25-000015 · edgardoc.xml · nonDerivative · entry 1 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,879 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.8900 to $115.1850, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 01:38 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,221 | $120.00 | $146,520.00 |
DisclosureSEC source: 0002001011-25-000011 · edgardoc.xml · nonDerivative · entry 7 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,879 F3 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 01:38 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 782 | $120.00 | $93,840.00 |
DisclosureSEC source: 0002001011-25-000011 · edgardoc.xml · nonDerivative · entry 6 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,100 F3 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 01:38 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,024 | $120.00 | $122,880.00 |
DisclosureSEC source: 0002001011-25-000011 · edgardoc.xml · nonDerivative · entry 5 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,882 F3 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 01:38 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 3,803 | $120.00 | $456,360.00 |
DisclosureSEC source: 0002001011-25-000011 · edgardoc.xml · nonDerivative · entry 4 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,906 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of performance stock units. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 01:38 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 7,390 | $0.00 | $0.00 |
DisclosureSEC source: 0002001011-25-000011 · edgardoc.xml · nonDerivative · entry 3 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,709 F1 · price: Represents shares of common stock issued upon the vesting and certification of performance stock units (PSUs). Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 01:38 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 2,757 | $120.00 | $330,840.00 |
DisclosureSEC source: 0002001011-25-000011 · edgardoc.xml · nonDerivative · entry 2 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,319 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of performance stock units. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 01:38 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 5,429 | $0.00 | $0.00 |
DisclosureSEC source: 0002001011-25-000011 · edgardoc.xml · nonDerivative · entry 1 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,076 F1 · price: Represents shares of common stock issued upon the vesting and certification of performance stock units (PSUs). Read SEC document |
| December 23, 2024 Filed Dec 27, 2024 01:32 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 2,104 | $116.37 | $244,850.48 |
DisclosureSEC source: 0002001011-24-000107 · edgardoc.xml · nonDerivative · entry 1 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,647 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.33 to $116.71, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 05, 2024 Filed Dec 7, 2024 00:55 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,859 | $123.51 | $229,605.09 |
DisclosureSEC source: 0002001011-24-000100 · edgardoc.xml · nonDerivative · entry 1 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,751 F1 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. Read SEC document |
| September 20, 2024 Filed Sep 24, 2024 23:41 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 800 | $103.95 | $83,160.00 |
DisclosureSEC source: 0002001011-24-000088 · edgardoc.xml · nonDerivative · entry 3 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,610 Read SEC document |
| September 20, 2024 Filed Sep 24, 2024 23:41 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 275 | $103.86 | $28,562.19 |
DisclosureSEC source: 0002001011-24-000088 · edgardoc.xml · nonDerivative · entry 2 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,410 Read SEC document |
| September 20, 2024 Filed Sep 24, 2024 23:41 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 200 | $103.98 | $20,796.00 |
DisclosureSEC source: 0002001011-24-000088 · edgardoc.xml · nonDerivative · entry 1 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,685 Read SEC document |
| September 17, 2024 Filed Sep 19, 2024 21:50 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,417 | $0.00 Strike: $80.72 | $0.00 |
DisclosureSEC source: 0002001011-24-000084 · edgardoc.xml · derivative · entry 4 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 466 Underlying: Common Stock · 1,417 shares Expires 2026-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| September 17, 2024 Filed Sep 19, 2024 21:50 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 69 | $0.00 Strike: $57.22 | $0.00 |
DisclosureSEC source: 0002001011-24-000084 · edgardoc.xml · derivative · entry 3 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,240 Underlying: Common Stock · 69 shares Expires 2030-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: As per the separation of OmniAb Inc. from the issuer, 4,096 stock options were vested and exercisable as of November 1, 2022, whereas 3,766 options vest in 23 substantially equal monthly installments beginning on December 1, 2022. Read SEC document |
| September 17, 2024 Filed Sep 19, 2024 21:50 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 69 | $57.22 | $3,948.18 |
DisclosureSEC source: 0002001011-24-000084 · edgardoc.xml · nonDerivative · entry 2 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,885 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 17, 2024 Filed Sep 19, 2024 21:50 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 1,417 | $80.72 | $114,380.24 |
DisclosureSEC source: 0002001011-24-000084 · edgardoc.xml · nonDerivative · entry 1 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 28, 2024 Filed Aug 31, 2024 01:00 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 546 | $0.00 Strike: $70.04 | $0.00 |
DisclosureSEC source: 0002001011-24-000080 · edgardoc.xml · derivative · entry 4 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 546 shares Expires 2029-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: As per the separation of OmniAb Inc. from the issuer, 402 stock options were vested and exercisable as of November 1, 2022, whereas 144 options vest in 3 substantially equal monthly installments beginning on December 1, 2022. Read SEC document |
| August 28, 2024 Filed Aug 31, 2024 01:00 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 207 | $0.00 Strike: $57.22 | $0.00 |
DisclosureSEC source: 0002001011-24-000080 · edgardoc.xml · derivative · entry 3 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,309 Underlying: Common Stock · 207 shares Expires 2030-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vests and is exercisable as to approximately 14% of the underlying shares on April 1, 2021, approximately 73% of the underlying shares in 32 substantially equal monthly installments on May 5, 2021, and approximately 13% of the underlying shares in 10 substantially equal monthly installments thereafter. Read SEC document |
| August 28, 2024 Filed Aug 31, 2024 01:00 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 546 | $70.04 | $38,241.84 |
DisclosureSEC source: 0002001011-24-000080 · edgardoc.xml · nonDerivative · entry 2 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,399 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 28, 2024 Filed Aug 31, 2024 01:00 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 207 | $57.22 | $11,844.54 |
DisclosureSEC source: 0002001011-24-000080 · edgardoc.xml · nonDerivative · entry 1 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,853 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 23:45 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | OtherCommon Stock | 267 | $60.71 | $16,208.77 |
DisclosureSEC source: 0002001011-24-000063 · edgardoc.xml · nonDerivative · entry 1 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,646 F1 · kind: These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| May 17, 2024 Filed May 17, 2024 23:59 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,022 | $0.00 Strike: $52.84 | $0.00 |
DisclosureSEC source: 0002001011-24-000053 · edgardoc.xml · derivative · entry 12 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,179 Underlying: Common Stock · 5,022 shares Expires 2032-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The stock option vests and is exercisable as to approximately 14% of the underlying shares on August 5, 2022, approximately 64% of the underlying shares in 28 substantially equal monthly installments beginning on September 5, 2022, and approximately 22% of the underlying shares in 12 substantially equal monthly installments thereafter. Read SEC document |
| May 17, 2024 Filed May 17, 2024 23:59 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 145 | $0.00 Strike: $68.74 | $0.00 |
DisclosureSEC source: 0002001011-24-000053 · edgardoc.xml · derivative · entry 11 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 145 shares Expires 2029-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option vests as to 50% of the underlying shares on January 11, 2023 and as to the remaining on February 11, 2023. Read SEC document |
| May 17, 2024 Filed May 17, 2024 23:59 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,544 | $0.00 Strike: $63.62 | $0.00 |
DisclosureSEC source: 0002001011-24-000053 · edgardoc.xml · derivative · entry 10 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,456 Underlying: Common Stock · 1,544 shares Expires 2032-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Grant to reporting person of stock options that will vest and become exercisable over a 4-year period measured from December 5, 2022, with 12-1/2% of the shares subject to the stock options vesting on the date that is six months after December 5, 2022 and the remaining stock options vesting in 42 equal monthly installments thereafter. Read SEC document |
| May 17, 2024 Filed May 17, 2024 23:59 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 206 | $0.00 Strike: $57.22 | $0.00 |
DisclosureSEC source: 0002001011-24-000053 · edgardoc.xml · derivative · entry 9 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,516 Underlying: Common Stock · 206 shares Expires 2030-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: As per the separation of OmniAb Inc. from the issuer, 4,096 stock options were vested and exercisable as of November 1, 2022, whereas 3,766 options vest in 23 substantially equal monthly installments beginning on December 1, 2022. Read SEC document |
| May 17, 2024 Filed May 17, 2024 23:59 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 134 | $86.65 | $11,611.06 |
DisclosureSEC source: 0002001011-24-000053 · edgardoc.xml · nonDerivative · entry 8 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,379 Read SEC document |
| May 17, 2024 Filed May 17, 2024 23:59 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 5,022 | $86.67 | $435,232.63 |
DisclosureSEC source: 0002001011-24-000053 · edgardoc.xml · nonDerivative · entry 7 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,513 F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $86.0300 to $86.8200. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 17, 2024 Filed May 17, 2024 23:59 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 5,022 | $52.84 | $265,362.48 |
DisclosureSEC source: 0002001011-24-000053 · edgardoc.xml · nonDerivative · entry 6 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2024 Filed May 17, 2024 23:59 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 145 | $68.74 | $9,967.30 |
DisclosureSEC source: 0002001011-24-000053 · edgardoc.xml · nonDerivative · entry 5 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2024 Filed May 17, 2024 23:59 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 1,544 | $63.62 | $98,229.28 |
DisclosureSEC source: 0002001011-24-000053 · edgardoc.xml · nonDerivative · entry 4 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,368 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2024 Filed May 17, 2024 23:59 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 206 | $57.22 | $11,787.32 |
DisclosureSEC source: 0002001011-24-000053 · edgardoc.xml · nonDerivative · entry 3 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 16, 2024 Filed May 17, 2024 23:59 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 2,264 | $86.00 | $194,711.70 |
DisclosureSEC source: 0002001011-24-000053 · edgardoc.xml · nonDerivative · entry 2 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,618 F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $86.0000 to $86.0350. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 15, 2024 Filed May 17, 2024 23:59 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 5,873 | $86.01 | $505,148.48 |
DisclosureSEC source: 0002001011-24-000053 · edgardoc.xml · nonDerivative · entry 1 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,882 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $86.0000 to $86.1500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 23:50 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 325 | $0.00 Strike: $58.49 | $0.00 |
DisclosureSEC source: 0002001011-24-000028 · edgardoc.xml · derivative · entry 8 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,607 Underlying: Common Stock · 325 shares Expires 2027-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 23:50 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 140 | $0.00 Strike: $57.22 | $0.00 |
DisclosureSEC source: 0002001011-24-000028 · edgardoc.xml · derivative · entry 7 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,722 Underlying: Common Stock · 140 shares Expires 2030-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: As per the separation of OmniAb Inc. from the issuer, 4,096 stock options were vested and exercisable as of November 1, 2022, whereas 3,766 options vest in 23 substantially equal monthly installments beginning on December 1, 2022. Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 23:50 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 799 | $0.00 Strike: $55.75 | $0.00 |
DisclosureSEC source: 0002001011-24-000028 · edgardoc.xml · derivative · entry 6 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,869 Underlying: Common Stock · 799 shares Expires 2030-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: As per the separation of OmniAb Inc. from the issuer, 2,039 stock options were vested and exercisable as of November 1, 2022, whereas 1,629 options vest in 16 substantially equal monthly installments beginning on November 13, 2022. Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 23:50 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 140 | $88.46 | $12,384.40 |
DisclosureSEC source: 0002001011-24-000028 · edgardoc.xml · nonDerivative · entry 5 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,755 Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 23:50 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 325 | $58.49 | $19,009.25 |
DisclosureSEC source: 0002001011-24-000028 · edgardoc.xml · nonDerivative · entry 4 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.